الفهرس 
Diiagnosiis of SLE
RESULTSOnly 14 pages are availabe for public view
 |  | from | 246 |  |  |
| | | from | 246 | | |
Abstract
SLE is a chronic, relapsing autoimmune disease that
can affect various organs, such as the skin, joints, kidneys, and
serosal membranes.
Renal involvement in SLE carries a poor prognosis
and significant morbidity and mortality. The 5- and 10-year
renal survival rates of lupus nephritis range between 83%–
92% and 74–84% respectively, up to 25% of patients still
develop end stage renal failure 10 years after onset of renal
disease. In 5% of cases renal abnormalities may occur up to
several years before other diagnostic criteria or serological
abnormalities become apparent.
Early clinical and histologic diagnosis of LN is pivotal
in order to minimize the risk of progression to ESRD. In this
setting, a renal biopsy is generally indicated in any case with
suspected lupus nephritis.
Kidney biopsy is an invasive procedure and
accompanied by potential risks. Thus defining a reliable
biomarker of kidney involvement in SLE is highly desirable.
Our cross sectional comparative study aimed at
quantitatively analyzing propotions and absolute cell numbers of
CD4+ CD25_ FoxP3+ Treg cells by flow cytometry (FACS) and
the correlation between findings, renal disease and SLEDAI score
in SLE was documented.